Circulating human papillomavirus Type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts

International Journal of Cancer

Volumn 121, Issue 12, 2007, Pages 2711-2715

  De Boer, Marjon A ^a   Jordanova, Ekaterina S ^a   Van Poelgeest, Mariëtte I E ^a   Van Den Akker, Brendy E ^a   Van Der Burg, Sjoerd H ^a   Kenter, Gemma G ^a   Fleuren, Gert Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer; HLA; Human papillomavirus; mRNA expression; T cell response

Indexed keywords

HLA ANTIGEN CLASS 1; MESSENGER RNA;

ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CIRCULATION; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; UTERINE CERVIX CANCER; VIRUS ONCOGENE;

ANTIGEN-PRESENTING CELLS; CARCINOMA; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; DOWN-REGULATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; NEOPLASM STAGING; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION, GENETIC; TUMOR VIRUS INFECTIONS; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 36249028112     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23035     Document Type: Article

References (33)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
2. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000;19:1-5.
3. zur Hausen HH. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
4. Sotlar K, Stubner A, Diemer D, Menton S, Menton M, Dietz K, Wallwiener D, Kandolf R, Bultmann B. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J Med Virol 2004;74:107-16.
5. Roggenbuck B, Larsen PM, Fey SJ, Bartsch D, Gissmann L, Schwarz E. Human papillomavirus type 18 E6*, E6, and E7 protein synthesis in cell-free translation systems and comparison of E6 and E7 in vitro translation products to proteins immunoprecipitated from human epithelial cells. J Virol 1991;65:5068-72.
6. Stern PL. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol 2005;32(Suppl 1):S72-81.
7. Wang SS, Hildesheim A. Chapter 5: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 2003;35-40.
8. Steele JC, Mann CH, Rookes S, Rollason T, Murphy D, Freeth MG, Gallimore PH, Roberts S. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer 2005;93:248-59.
9. de Gruijl TD, Bontkes HJ, Stukart MJ, Walboomers JM, Remmink AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ, Scheper RJ. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J Gen Virol 1996;77(Part 9):2183-91.
10. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004;64:5449-55.
11. Natarajan K, Li H, Mariuzza RA, Margulies DH. MHC class I molecules, structure and function. Rev Immunogenet 1999;1:32-46.
12. Breitburd F, Ramoz N, Salmon J, Orth G. HLA control in the progression of human papillomavirus infections. Semin Cancer Biol 1996;7: 359-71.
13. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 1997;18:89-95.
14. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000;191:961-76.
15. Chil A, Sikorski M, Bobek M, Jakiel G, Marcinkiewicz J. Alterations in the expression of selected MHC antigens in premalignant lesions and squamous carcinomas of the uterine cervix. Acta Obstet Gynecol Scand 2003;82:1146-52.
16. Connor ME, Stern PL. Loss of MHC class-I expression in cervical carcinomas. Int J Cancer 1990;46:1029-34.
17. Keating PJ, Cromme FV, Duggan-Keen M, Snijders PJ, Walboomers JM, Hunter RD, Dyer PA, Stern PL. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995;72:405-11.
18. Hilders CG, Munoz IM, Nooyen Y, Fleuren GJ. Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol 1995;57:366-75.
19. Claas EC, Melchers WJ, van der Linden HC, Lindeman J, Quint WG. Human papillomavirus detection in paraffin-embedded cervical carcinomas and metastases of the carcinomas by the polymerase chain reaction. Am J Pathol 1989;135:703-9.
20. van der Burg SH, Kwappenberg KM, Geluk A, van der Kruk M, Pontesilli O, Hovenkamp E, Franken KL, van Meijgaarden KE, Drijfhout JW, Ottenhoff TH, Melief CJ, Offringa R. Identification of conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. J Immunol 1999;162:152-60.
21. de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ, Offringa R. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002;62:472-9.
22. van der Burg SH, Menon AG, Redeker A, Franken KL, Drijfhout JW, Tollenaar RA, Hartgrink HH, van de Velde CJ, Kuppen PJ, Melief CJ, Offringa R. Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors. Int J Cancer 2003;107:425-33.
23. De Boer MA, Jordanova ES, Kenter GG, Peters AA, Corver WE, Trimbos JB, Fleuren GJ. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clin Cancer Res 2007;13:132-8.
24. Corver WE, Ter Haar NT, Dreef EJ, Miranda NF, Prins FA, Jordanova ES, Cornelisse CJ, Fleuren GJ. High-resolution multi-parameter DNA How cytometry enables detection of tumor and stromal cell subpopulations in paraffin-embedded tissues. J Pathol 2005;206:233-41.
25. Vermeulen CF, Jordanova ES, Zomerdijk-Nooijen YA, Ter Haar NT, Peters AA, Fleuren GJ. Frequent HLA class I loss is an early event in cervical carcinogenesis. Hum Immunol 2005;66:1167-73.
26. Ruiter DJ, Ferrier CM, van Muijen GN, Henzen-Logmans SC, Kennedy S, Kramer MD, Nielsen BS, Schmitt M. Quality control of immunohistochemical evaluation of tumor-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumor Invasion and Metastasis. Eur J Cancer 1998;34:1334-40.
27. Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007;67:354-61.
28. Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gileadi U, Cerundolo V, Man S. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 2001;167:5420-8.
29. Bontkes HJ, Walboomers JM, Meijer CJ, Helmerhorst TJ, Stern PL. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet 1998;351:187-8.
30. van Driel WJ, Tjiong MY, Hilders CG, Trimbos BJ, Fleuren GJ. Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma. Gynecol Oncol 1996;62:33-41.
31. Harada M, Matsueda S, Yao A, Noguchi M, Itoh K. Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patient. J Immunother 2005;28:368-75.
32. Dorries R. The role of T-cell-mediated mechanisms in virus infections of the nervous system. Curr Top Microbiol Immunol 2001;253:219-45.
33. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, Scott B. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol 2000;165:6047-55.